[go: up one dir, main page]

WO2005095644A3 - Verfahren zur erkennung von signaturen in komplexen genexpressionsprofilen - Google Patents

Verfahren zur erkennung von signaturen in komplexen genexpressionsprofilen Download PDF

Info

Publication number
WO2005095644A3
WO2005095644A3 PCT/EP2005/003520 EP2005003520W WO2005095644A3 WO 2005095644 A3 WO2005095644 A3 WO 2005095644A3 EP 2005003520 W EP2005003520 W EP 2005003520W WO 2005095644 A3 WO2005095644 A3 WO 2005095644A3
Authority
WO
WIPO (PCT)
Prior art keywords
expression profile
complex
expression profiles
determining
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/003520
Other languages
English (en)
French (fr)
Other versions
WO2005095644A2 (de
Inventor
Thomas Haeupl
Joachim Gruen
Andreas Radbruch
Gerd-Ruediger Burmester
Christian Kaps
Andreas Gruetzkau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OLIGENE GmbH
Original Assignee
OLIGENE GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OLIGENE GmbH filed Critical OLIGENE GmbH
Priority to US11/547,040 priority Critical patent/US20080108509A1/en
Priority to EP05716523A priority patent/EP1733050A2/de
Publication of WO2005095644A2 publication Critical patent/WO2005095644A2/de
Publication of WO2005095644A3 publication Critical patent/WO2005095644A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen, das die Schritte umfasst von: a) zur Verfügung stellen einer zu unter­suchenden biologischen Probe, b) zur Verfügung stellen mindestens eines geeigneten Expres­sionsprofils, wobei das mindestens eine Expressionsprofil einen oder mehrere Marker umfasst, die ausschliesslich für das Expressionsprofil typisch sind, c) Bestimmen des komplexen Ex­pressionsprofils d er b iologischen Probe, d) Bestimmen der quantitativen zellulären Z usam­mensetzung der biologischen Probe mittels der in den Schritten b) und c) bestimmten Expres­sionsprofile. Weiterhin kann das erfindungsgemässe Verfahren die Schritte von e) Berechnung eines virtuellen Signals, das aufgrund der bestimmten Zusammensetzung der Expressionspro­file erwartet wird, f) Berechnung der Differenz aus dem tatsächlichem gemessenem komple­xen Expressionsprofils und dem virtuellen Signal, und g) Bestimmen der quantitativen Zu­sammensetzung des komplexen Expressionsprofils auf Basis der ermittelten Differenzen um­fassen. Die vorliegende Erfindung betrifft weiterhin die Anwendung des erfindungsgemässen Verfahrens in der Diagnose, Prognose und/oder Verfolgung einer Erkrankung. Schliesslich werden entsprechende Computersysteme, Computerprogramme, computerlesbare Datenträ­germedien und Laborroboter oder Auswertegeräte für molekulare Nachweismethoden offenbart.
PCT/EP2005/003520 2004-04-04 2005-04-04 Verfahren zur erkennung von signaturen in komplexen genexpressionsprofilen Ceased WO2005095644A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/547,040 US20080108509A1 (en) 2004-04-04 2005-04-04 Process for Recognizing Signatures in Complex Gene Expression Profiles
EP05716523A EP1733050A2 (de) 2004-04-04 2005-04-04 Verfahren zur erkennung von signaturen in komplexen genexpressionsprofilen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004016437A DE102004016437A1 (de) 2004-04-04 2004-04-04 Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen
DE102004016437.1 2004-04-04

Publications (2)

Publication Number Publication Date
WO2005095644A2 WO2005095644A2 (de) 2005-10-13
WO2005095644A3 true WO2005095644A3 (de) 2006-04-13

Family

ID=34979107

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/003520 Ceased WO2005095644A2 (de) 2004-04-04 2005-04-04 Verfahren zur erkennung von signaturen in komplexen genexpressionsprofilen

Country Status (4)

Country Link
US (1) US20080108509A1 (de)
EP (1) EP1733050A2 (de)
DE (1) DE102004016437A1 (de)
WO (1) WO2005095644A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
WO2008066878A2 (en) * 2006-11-29 2008-06-05 University Of Vermont And State Agricultural College Methods and products for diagnosing cancer
WO2008134020A1 (en) 2007-04-26 2008-11-06 University Of Vermont And State Agricultural College Ccl18 and ccl3 methods and compositions for detecting and treating cancer
GB0722582D0 (en) * 2007-11-16 2007-12-27 Secr Defence Early detection of sepsis
KR20100105776A (ko) * 2008-01-18 2010-09-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법
WO2010032816A1 (ja) * 2008-09-19 2010-03-25 小野薬品工業株式会社 新規リゾホスファチジルセリン受容体
CA2742380C (en) 2008-11-07 2018-05-29 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US8691510B2 (en) * 2008-11-07 2014-04-08 Sequenta, Inc. Sequence analysis of complex amplicons
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
ES2568509T3 (es) 2009-01-15 2016-04-29 Adaptive Biotechnologies Corporation Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales
KR20120060948A (ko) * 2009-05-29 2012-06-12 더 리전트 오브 더 유니버시티 오브 캘리포니아 이식 수혜자에서 관용과 연관된 ｂ 세포 시그너쳐
EP2446052B1 (de) 2009-06-25 2018-08-08 Fred Hutchinson Cancer Research Center Verfahren zur messung der adaptiven immunität
RU2539112C2 (ru) * 2009-09-03 2015-01-10 Дженентек, Инк. Способы лечения, диагностики и мониторинга ревматоидного артрита
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
EP2385134A1 (de) * 2010-05-07 2011-11-09 Ludwig-Maximilians-Universität München Risikoprognoseverfahren für chronische lymphatische Leukämie
US20130266940A1 (en) * 2010-07-23 2013-10-10 President And Fellows Of Harvard College Methods of Detecting Kidney-Associated Diseases or Conditions
EP2596353A4 (de) 2010-07-23 2014-01-15 Harvard College Verfahren zum nachweis pränataler oder schwangerschaftsvermittelter krankheiten oder leiden
AU2011280997A1 (en) * 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
US9279159B2 (en) 2011-10-21 2016-03-08 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
CA2858070C (en) 2011-12-09 2018-07-10 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
WO2013134162A2 (en) 2012-03-05 2013-09-12 Sequenta, Inc. Determining paired immune receptor chains from frequency matched subunits
PT2831276T (pt) 2012-05-08 2016-07-26 Adaptive Biotechnologies Corp Composições e método para medição e calibração do viés de amplificação em reações pcr multiplex
WO2014016284A1 (en) * 2012-07-23 2014-01-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing scleroderma
EP2904111B1 (de) 2012-10-01 2017-12-06 Adaptive Biotechnologies Corporation Immunkompetenzbeurteilung durch adaptive immunrezeptordiversität und klonalitätscharakterisierung
EP2965077B1 (de) 2013-03-09 2022-07-13 Harry Stylli Verfahren zur krebserkennung
JP6590790B2 (ja) * 2013-04-19 2019-10-16 エピオンティス ゲーエムベーハー 生体サンプルにおける定量的細胞組成を特定する方法
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
US20170292149A1 (en) 2014-03-05 2017-10-12 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
EP3132059B1 (de) 2014-04-17 2020-01-08 Adaptive Biotechnologies Corporation Quantifizierung von adaptiven immunzellgenomen in einer komplexen mischung von zellen
EP3715455A1 (de) 2014-10-29 2020-09-30 Adaptive Biotechnologies Corp. Hochmultiplexierter gleichzeitiger nachweis von für adaptive gepaarte immunrezeptorheterodimere codierenden nukleinsäuren aus einer vielzahl von proben
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
US11066705B2 (en) 2014-11-25 2021-07-20 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
US11047008B2 (en) 2015-02-24 2021-06-29 Adaptive Biotechnologies Corporation Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing
CA2979726A1 (en) 2015-04-01 2016-10-06 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
WO2023222927A2 (en) * 2022-05-20 2023-11-23 Novigenix Sa Biomarkers for colorectal neoplasia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104394A1 (en) * 2001-12-03 2003-06-05 Xudong Dai Method and system for gene expression profiling analysis utilizing frequency domain transformation
DE10159404A1 (de) * 2001-12-04 2003-06-26 Arevia Gmbh Verfahren zur Analyse von Gewebeproben
WO2005028677A2 (en) * 2003-05-07 2005-03-31 Agilent Technologies, Inc. Systems and methods for determining cell type composition of mixed cell populations using gene expression signatures

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005882A2 (en) * 2001-06-18 2004-01-15 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (mphts)
MXPA04008414A (es) * 2002-02-28 2005-06-08 Iconix Pharm Inc Indicaciones de farmacos.
US20030186248A1 (en) * 2002-03-29 2003-10-02 Erlander Mark G. Interpreting cytological specimens via molecular histological signatures

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104394A1 (en) * 2001-12-03 2003-06-05 Xudong Dai Method and system for gene expression profiling analysis utilizing frequency domain transformation
DE10159404A1 (de) * 2001-12-04 2003-06-26 Arevia Gmbh Verfahren zur Analyse von Gewebeproben
WO2005028677A2 (en) * 2003-05-07 2005-03-31 Agilent Technologies, Inc. Systems and methods for determining cell type composition of mixed cell populations using gene expression signatures

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
BOYLE DAVID L ET AL: "Quantitative biomarker analysis of synovial gene expression by real-time PCR.", ARTHRITIS RESEARCH & THERAPY. 2003, vol. 5, no. 6, 2003, pages R352 - R360, XP009054833, ISSN: 1478-6362 *
CHURCHILL GARY A: "Using ANOVA to analyze microarray data", BIOTECHNIQUES, vol. 37, no. 2, August 2004 (2004-08-01), pages 173 - 175, 177, XP001207478, ISSN: 0736-6205 *
CUI X ET AL.: "Transformations for cDNA Microarray Data", STAT. APPL. GENET. MOL. BIOL., vol. 2, no. 1, 2003, pages ARTICLE 4, XP009054792 *
CUI XIANGQIN ET AL: "Statistical tests for differential expression in cDNA microarray experiments.", GENOME BIOLOGY 2003, vol. 4, no. 4, 2003, pages 210.1 - 210.10, XP002347523, ISSN: 1465-6914 *
CUIDA MIHAELA ET AL: "Immunohistochemical characterization of the cellular infiltrates in Sjogren's syndrome, rheumatoid arthritis and osteoarthritis with special reference to calprotectin-producing cells", APMIS, vol. 104, no. 12, 1996, pages 881 - 890, XP009054813, ISSN: 0903-4641 *
EISEN M B ET AL: "Cluster analysis and display of genome-wide expression patterns", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, December 1998 (1998-12-01), pages 14863 - 14868, XP002140966, ISSN: 0027-8424 *
HERSMANN G H ET AL: "Expression of cell adhesion molecules and cytokines in murine antigen-induced arthritis.", CELL ADHESION AND COMMUNICATION. JUN 1998, vol. 6, no. 1, June 1998 (1998-06-01), pages 69 - 82, XP009054855, ISSN: 1061-5385 *
IBRAHIM SALEH MOHAMED ET AL: "Gene-expression profile of collagen-induced arthritis", JOURNAL OF AUTOIMMUNITY, vol. 18, no. 2, March 2002 (2002-03-01), pages 159 - 167, XP002347525, ISSN: 0896-8411 *
ISSEKUTZ A C ET AL: "Treatment of established adjuvant arthritis in rats with monoclonal antibody to CD18 and very late activation antigen-4 integrins suppresses neutrophil and T-lymphocyte migration to the joints and improves clinical disease.", IMMUNOLOGY. AUG 1996, vol. 88, no. 4, August 1996 (1996-08-01), pages 569 - 576, XP002347521, ISSN: 0019-2805 *
KERR K ET AL: "ANALYSIS OF VARIANCE FOR GENE EXPRESSON MICROARRAY DATA", JOURNAL OF COMPUTATIONAL BIOLOGY, MARY ANN LIEBERT, LARCHMONT, NY, US, vol. 7, no. 6, December 2000 (2000-12-01), pages 819 - 837, XP009036796, ISSN: 1066-5277 *
KURELLA ET AL: "DNA microarray analysis of complex biologic processes", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 12, 2001, pages 1072 - 1078, XP002253149, ISSN: 1046-6673 *
MARTOGLIO ANN-MARIE ET AL: "A decomposition model to track gene expression signatures: preview on observer-independent classification of ovarian cancer.", BIOINFORMATICS (OXFORD, ENGLAND) DEC 2002, vol. 18, no. 12, December 2002 (2002-12-01), pages 1617 - 1624, XP002347522, ISSN: 1367-4803 *
MCMURRAY R W: "Adhesion molecules in autoimmune disease", SEMINARS IN ARTHRITIS AND RHEUMATISM, vol. 25, no. 4, February 1996 (1996-02-01), pages 215 - 233, XP004680749, ISSN: 0049-0172 *
MURALI T M ET AL: "Extracting conserved gene expression motifs from gene expression data.", PACIFIC SYMPOSIUM ON BIOCOMPUTING. PACIFIC SYMPOSIUM ON BIOCOMPUTING., 2003, pages 77 - 88, XP002347524 *
VAN DER POUW KRAAN TINEKE C T M ET AL: "Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues.", ARTHRITIS AND RHEUMATISM. AUG 2003, vol. 48, no. 8, August 2003 (2003-08-01), pages 2132 - 2145, XP002347526, ISSN: 0004-3591 *
VENET D ET AL: "Separation of samples into their constituents using gene expression data", BIOINFORMATICS, OXFORD UNIVERSITY PRESS, OXFORD, GB, vol. 17 Suppl 1, 2001, pages S279 - S287, XP002327802, ISSN: 1367-4803 *
WEITZ-SCHMIDT G ET AL: "STATINS SELECTIVELY INHIBIT LEUKOCYTE FUNCTION ANTIGEN-1 BY BINDINGTO A NOVEL REGULATORY INTEGRIN SITE", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 7, no. 6, June 2001 (2001-06-01), pages 687 - 692, XP001027602, ISSN: 1078-8956 *
YUSUF-MAKAGIANSAR H ET AL: "INHIBITION OF LFA-1/ICAM-1 AND VLA-4/VCAM-1 AS A THERAPEUTIC APPROACH TO INFLAMMATION AND AUTOIMMUNE DISEASES", MEDICINAL RESEARCH REVIEWS, NEW YORK, NY, US, vol. 22, no. 2, March 2002 (2002-03-01), pages 146 - 167, XP009034558, ISSN: 0198-6325 *

Also Published As

Publication number Publication date
WO2005095644A2 (de) 2005-10-13
US20080108509A1 (en) 2008-05-08
EP1733050A2 (de) 2006-12-20
DE102004016437A1 (de) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2005095644A3 (de) Verfahren zur erkennung von signaturen in komplexen genexpressionsprofilen
Betsou et al. Identification of evidence-based biospecimen quality-control tools: a report of the International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group
WO2006126008A3 (en) Improved immunoassay methods
WO2009057695A1 (ja) 遺伝子解析による腺腫又はがんの検出方法
WO2008011046A3 (en) Computer systems and methods for selecting subjects for clinical trials
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2007092627A3 (en) Detection of cancer by elevated levels of bcl-2
WO2007133586A3 (en) Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets
WO2006023769A3 (en) Determining data quality and/or segmental aneusomy using a computer system
WO2008063413A3 (en) Gene expression profiling for identification, monitoring, and treatment of lung cancer
WO2007127749A3 (en) Predicting mortality and detecting severe disease
WO2008119081A8 (en) System and method for high resolution analysis of nucleic acids to detect sequence variations
WO2008128043A3 (en) Diagnostic and prognostic methods for renal cell carcinoma
CN103097548A (zh) 基于多癌症侵袭相关机制的生物标记
WO2005080602A3 (en) Immunological detection of rna:dna hybrids on microarrays
US12270814B2 (en) Kits and methods for prediction and treatment of preeclampsia
WO2004057336A3 (en) Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
WO2009026381A3 (en) Method, computer program product and system for individual assessment of alcohol sensitivity
WO2008020823A3 (en) Cooperative reporter systems, components, and methods for analyte detection
EP2520669A3 (de) Biomarker für milde Arthrose und Verwendungen davon
WO2008116178A3 (en) Systems and methods for diagnosis and prognosis of colorectal cancer
WO2007103211A3 (en) Methods to identify fat and lean animals using class predictors
WO2005124356A3 (en) Use of protein cbp2 as a marker for colorectal cancer
Ye et al. Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring
FR2900936B1 (fr) Procede et methodes de detection de la maladie d'alzheimer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005716523

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005716523

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11547040

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2005716523

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11547040

Country of ref document: US